5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Europe Nuclear Medicine Market is segmented by Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy), Application (Cardiology, Neurology, Oncology, Other Applications), and Geography
Increasing incidence of cancer and cardiac ailments is the major driver of the market. Nuclear medicine shows a huge potential in treating cardiac and cancer diseases. According to WHO, it is estimated that 3.7 million new cases and 1.9 million deaths occur every year due to cancer, and cancer disease represents the second most significant cause of death and morbidity in Europe. Cardiology applications will continue to demonstrate strong growth in the market. Other factors, such as increasing SPECT and PET applications and growing public awareness for healthcare are also expected to drive the market in the future.
Regulatory requirements pose another hurdle to translational research and clinical investigations. In Europe, all the guidelines for nuclear medicine products are coordinated by the European Association of Nuclear Medicine (EANM) and, including diagnostic radiopharmaceuticals and radio therapeutics, undergo regulatory procedures by European Medicines Agency (EMEA). Radiopharmaceuticals undergo unique regulatory and approval pathways. Sometimes, extensive toxicology testing poses considerable financial burdens for the investigators.
As per the scope of the report, Nuclear medicine falls under the field of molecular imaging, which involves the use of a very small amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
Report scope can be customized per your requirements. Click here.
The application segment is further sub-segmented into cardiology, neurology, oncology, and other applications. The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases (CVD) over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died, due to CVDs. The cardiology segment of the market studied is expected to have a positive contribution in the market growth.
To understand key trends, Download Sample Report
There is high competition among the players of the global nuclear medicine market. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. The major players in the Europe nuclear medicine market include Advanced Accelerator Applications, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Isotec Inc. (Sigma-Aldrich), Mallinckrodt Pharmaceuticals, Nordion Inc., and Siemens AG.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidents of Cancer and Cardiac Ailments
4.2.2 Increasing SPECT and PET Applications
4.2.3 Growing Public Awareness for Healthcare
4.3 Market Restraints
4.3.1 Strict Regulatory Guidelines
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.2.1 Alpha Emitters
5.2.2 Beta Emitters
5.3.4 Other Applications
18.104.22.168 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Advanced Accelerator Applications
6.1.2 Bracco Imaging SpA
6.1.3 Cardinal Health Inc.
6.1.4 Curium Pharma
6.1.5 GE Healthcare
6.1.6 Isotec Inc. (Sigma-Aldrich)
6.1.7 Mallinckrodt Pharmaceuticals
6.1.8 Nordion Inc.
6.1.9 Siemens AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments